“Our findings have important clinical implications. … By decreasing the background (blood pool) signal, not only do the target-to-background values improve, but also lesions which were difficult to detect one hour post injection can be easily identified,” wrote the researchers led by Dr. Jacek Kwiecinski from Cedars-Sinai Medical Center. {read more here}

Amyloid load (AβL) imaged in vivo using [18F]Florbetapir PET is a more sensitive biomarker for measuring the global amyloid (Aβ) burden compared to composite standardized uptake value ratio (SUVr), study reported authors of a Sept. 6 Journal of Nuclear Medicine study. {read more here}

Aortic vascular inflammation, detected by F18 positron emission tomography/CT (18F-FDG PET/CT), was linked with coronary artery disease (CAD) based on coronary CT angiography (CCTA) among psoriasis patients in a cross-sectional cohort study. {read more here}

Eli Lilly and Company and its wholly-owned subsidiary Avid Radiopharmaceuticals, announced the successful Phase III trial of a Positron Emission Tomography (PET) imaging agent, flortaucipr F 18, in identifying tau in the brains of late-stage Alzheimer’s patients. {read more here}